JNJ•benzinga•June 3, 2025 at 02:49 PM

Johnson & Johnson Announces Data From Two Studies Highlighting That DARZALEX FASPRO-Based Quadruplet Regimen Demonstrated Deep And Sustained MRD Negativity Rates, And Improved Long-Term PFS In NDMM Patients

No summary available.

Read the full article from the original source for complete details and context.

Article published on June 3, 2025 by benzinga